ScholarIQanswers from OpenAlex
Karl Landsteiner Society
InstitutionResearch output, impact & collaborations
Karl Landsteiner Society is a institution indexed in ScholarIQ from OpenAlex.
What is known about Karl Landsteiner Society?
ScholarIQrecord summary
Karl Landsteiner Society is a research organisation in St. Pölten, AT. OpenAlex records 2,844 works and 97,051 citations for it. 593 researchers list it as their most recent affiliation.
How many works does Karl Landsteiner Society have?
ScholarIQindexed works
Karl Landsteiner Society has 2,844 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Karl Landsteiner Society have?
ScholarIQcitation count
Karl Landsteiner Society has 97,051 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Karl Landsteiner Society?
ScholarIQresearcher count
Karl Landsteiner Society has 593 researchers in the ScholarIQ index.
What is the average h-index at Karl Landsteiner Society?
ScholarIQavg h-index
Karl Landsteiner Society has an average h-index of 66 in OpenAlex.
What is the ROR of Karl Landsteiner Society?
ScholarIQror
The ROR for Karl Landsteiner Society is on the source record.
What is the OpenAlex record for Karl Landsteiner Society?
ScholarIQopenalex
The OpenAlex for Karl Landsteiner Society is on the source record.
Who are the most-cited researchers behind Karl Landsteiner Society?
ScholarIQtop researchers by citations
What are the most-cited papers on Karl Landsteiner Society?
ScholarIQmost cited works
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer
Jürgen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Toyoaki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian J. Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R. Overbeck, Filippo de Marinis, Tae Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaër, Maeve Waldron-Lynch, B. Sankaran, O. Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S. Heist
Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer
D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Jong Seok Lee, Maximilian J. Hochmair, Jacky Yu-Chung Li, Gee‐Chen Chang, Ki Hyeong Lee, Cesare Gridelli, Angelo Delmonte, Rosario García Campelo, Dong‐Wan Kim, Alessandra Bearz, Frank Griesinger, Alessandro Morabito, Enriqueta Felip, Raffaele Califano, Sharmistha Ghosh, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Neeraj Gupta, J. Haney, David Kerstein, Sanjay Popat
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Gálffy, Maximilian J. Hochmair, Thomas Winder, Р. А. Зуков, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang‐Yun Lee, Lorenzo Antonuzzo, Zsolt Pápai-Székely, Hiroaki Akamatsu, Bivas Biswas, Alexander I. Spira, Jeffrey Crawford, Ha Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
Marina Chiara Garassino, Shirish M. Gadgeel, Giovanna Speranza, Enriqueta Felip, Emilio Esteban, Manuel Dómine, Maximilian J. Hochmair, Steven Powell, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Rina Hui, Edward B. Garon, Takayasu Kurata, Jhanelle E. Gray, Paul Schwarzenberger, Erin Jensen, M. Catherine Pietanza, Delvys Rodríguez‐Abreu
How much of the research on Karl Landsteiner Society is open access?
ScholarIQopen access share
100%OPEN ACCESS